Inventor · disambiguated record
Bryan R. Wilson
Also filed as: WILSON BRYAN · WILSON BRYAN R
25 granted patents·8 pending applications·389 citations·filing 1995–2025
96Inventor score
Files withMANNKIND CORP20CARA THERAPEUTICS INC5BIODEL INC4LEONE-BAY ANDREA2PHARMACEUTICAL DISCOVERY CORP1
Top patents by PatentIndex Score
33 records- 0199US7820676B2Diketopiperazine salts for drug delivery and related methodsMANNKIND CORP·Filed 2005·Granted Oct 26, 2010·81 cites·13 claims
- 0298US8039431B2Method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agentMANNKIND CORP·Filed 2007·Granted Oct 18, 2011·58 cites·16 claims
- 0398US7833550B2Dry powder formulations of antihistamine for nasal administrationMANNKIND CORP·Filed 2007·Granted Nov 16, 2010·40 cites·13 claims
- 0497US8278308B2Diketopiperazine salts for drug delivery and related methodsLEONE-BAY ANDREA·Filed 2010·Granted Oct 2, 2012·58 cites·14 claims
- 0595US8512932B2Method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agentWILSON BRYAN R·Filed 2011·Granted Aug 20, 2013·54 cites·27 claims
- 0693US10130685B2Diketopiperazine salts for drug delivery and related methodsMANNKIND CORP·Filed 2017·Granted Nov 20, 2018·8 cites·19 claims
- 0793US7833549B2Dry powder formulations of antihistamine for nasal administrationMANNKIND CORP·Filed 2001·Granted Nov 16, 2010·39 cites·17 claims
- 0892US10912821B2Diketopiperazine salts for drug delivery and related methodsMANNKIND CORP·Filed 2020·Granted Feb 9, 2021·2 cites·18 claims
- 0990US9259471B2Diketopiperazine salts for drug delivery and related methodsMANNKIND CORP·Filed 2014·Granted Feb 16, 2016·8 cites·21 claims
- 1090US8653085B2Diketopiperazine salts for drug delivery and related methodsLEONE-BAY ANDREA·Filed 2012·Granted Feb 18, 2014·8 cites·16 claims
- 1189US9675674B2Diketopiperazine salts for drug delivery and related methodsMANNKIND CORP·Filed 2016·Granted Jun 13, 2017·4 cites·20 claims
- 1288US9381247B2Magnesium compositions for modulating the pharmacokinetics and pharmacodynamics of insulin and insulin analogs, and injection site painBIODEL INC·Filed 2013·Granted Jul 5, 2016·6 cites·25 claims
- 1387US11684674B2Oral formulations of kappa opioid receptor agonistsCARA THERAPEUTICS INC·Filed 2021·Granted Jun 27, 2023·1 cites·20 claims
- 1487US11033629B2Oral formulations of kappa opioid receptor agonistsCARA THERAPEUTICS INC·Filed 2019·Granted Jun 15, 2021·4 cites·20 claims
- 1587US2023414500A1Method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agentMANNKIND CORP·Filed 2023·Application pending·0 cites
- 1686US10583176B2Diketopiperazine salts for drug delivery and related methodsMANNKIND CORP·Filed 2018·Granted Mar 10, 2020·2 cites·19 claims
- 1781US10421729B2Microcrystalline diketopiperazine compositions and methodsMANNKIND CORP·Filed 2014·Granted Sep 24, 2019·3 cites·21 claims
- 1881US9399065B2Magnesium compositions for modulating the pharmacokinetics and injection site pain of insulinBIODEL INC·Filed 2014·Granted Jul 26, 2016·3 cites·23 claims
- 1979US9241903B2Method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agentMANNKIND CORP·Filed 2013·Granted Jan 26, 2016·2 cites·24 claims
- 2078US11872265B2Diketopiperazine salts for drug delivery and related methodsMANNKIND CORP·Filed 2021·Granted Jan 16, 2024·0 cites·20 claims
- 2178US2025154113A1Microcrystalline Diketopiperazine Compositions and MethodsMANNKIND CORP·Filed 2025·Application pending·0 cites
- 2276US10130581B2Method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agentMANNKIND CORP·Filed 2015·Granted Nov 20, 2018·1 cites·14 claims
- 2376US2023338546A1Oral formulations of kappa opioid receptor agonistsCARA THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2475US2022048868A1Microcrystalline Diketopiperazine Compositions and MethodsMANNKIND CORP·Filed 2021·Application pending·0 cites
- 2573US2023381265A1Oligosaccharide formulations of kappa opioid receptor agonistsCARA THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2671US11192862B2Microcrystalline diketopiperazine compositions and methodsMANNKIND CORP·Filed 2020·Granted Dec 7, 2021·0 cites·9 claims
- 2769US11986509B2Oligosaccharide formulations of kappa opioid receptor agonistsCARA THERAPEUTICS INC·Filed 2021·Granted May 21, 2024·0 cites·11 claims
- 2869US10745359B2Microcrystalline diketopiperazine compositions and methodsMANNKIND CORP·Filed 2019·Granted Aug 18, 2020·0 cites·11 claims
- 2969US10376466B2Method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agentMANNKIND CORP·Filed 2018·Granted Aug 13, 2019·0 cites·6 claims
- 3069US2019314276A1Method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agentMANNKIND CORP·Filed 2019·Application pending·0 cites
- 3150US2014336610A1Methods and devices for point of use mixing of pharmaceutical formulationsBIODEL INC·Filed 2014·Application pending·0 cites
- 3241US5712269AM2 receptor ligand for the treatment of neurological disordersPHARMACEUTICAL DISCOVERY CORP·Filed 1995·Granted Jan 27, 1998·7 cites·10 claims
- 3340US2015273022A1Stabilized ultra-rapid-acting insulin formulationsBIODEL INC·Filed 2015·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →